193 results about "Cannabivarin" patented technology

A method of producing a cannabinoid nanoparticle carrier composition for administration to a human and thereafter producing a consumable food product including the cannabinoid nanoparticle emulsification. The cannabinoid nanoparticle carrier composition is combined with a particulate food product, herb or spice, sugar, salt, or particulate preservative, mixed into a slurry or suspension, dried, and then ground to a size suitable for human consumption.

The present invention relates to the use of cannabidiol (CBD) in the treatment of epilepsy which results from mutation of the KCNT1 gene. The CBD used is in the form of a highly purified extract of Cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) is present in an amount of from 0.02 to 0.1% (w / w). In an alternative embodiment the CBD may be in a synthetic form. In use the CBD may also be used concomitantly with one or more other anti-epileptic drugs (AED). The CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form. Where the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated. It may also be used as the sole medication, i.e. as a monotherapy.

Disclosed herein are polycannabinoids compositions which find use as a commodity polymer and for commodity electronics.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking immunosuppressant drugs. In particular the immunosuppressant drug is a calcineurin inhibitor. More particularly the immunosuppressant drug is tacrolimus. Where the CBD is used in combination with an immunosuppressant drug, caution should be taken. For example, the dose of either the CBD and / or the immunosuppressant drug may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The invention discloses a hyperbranched anion exchange magnetic solid-phase extraction adsorbent as well as a preparation method and application thereof. The adsorbent Fe3O4 (at) poly (GMA / DVB-WAX) is obtained by carrying out hyperbranched anion modification on Fe3O4 (at) poly (GMA / DVB) microspheres through ethylenediamine and 1, 4-butanediol glycidyl ether. Compared with an Oasis MCX adsorbent and an Oasis HLB adsorbent, the adsorbent provided by the invention has better extraction efficiency. Compared with a column type solid-phase extraction method, the magnetic solid-phase extraction method provided by the invention has the advantages that the sample can be directly extracted without being filtered, the pretreatment step is simplified, and the sensitivity of the method is improved. The invention also establishes a magnetic solid phase extraction-ultra-high performance liquid chromatography-mass spectrometry (MSPE-UHPLC-MS / MS) method for determining four cannabinoids, namely tetrahydrocannabinol, cannabidiol, cannabinol and tetrahydrocannabinoic acid, in the sewage, and the method has the advantages of short pretreatment time, simplicity and convenience in operation, sensitivity and accuracy, and can be used for detecting the four cannabinoids, namely the tetrahydrocannabinol, the cannabidiol, the cannabinol and the tetrahydrocannabinoic acid in the sewage. The trace analysis of the four cannabinoids in the sewage can be met, and the method has very high practicability.

Nuts and related foodstuffs are contacted with / by cannabinoids, including hemp derived Delta8 / 9 via several different mechanisms, whereby the cannabinoids are attached, infused, coated, adhesed, adhered, and otherwise attached to said nuts and related foodstuffs, for ingestion by humans.

Described are liquid compositions that contain a desired (e.g., extracted) plant material such as cannabinoid, terpene, terpenoid, or the like, contained, e.g., dissolved, suspended, or emulsified, in the liquid, which contains surfactant; methods of preparing these types of liquid compositions; and methods of processing this type of liquid composition to collect, isolate, concentrate, or purify a desired target material contained in the liquid composition.

The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD ap-pears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocan-nabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The present disclosure relates to the use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease. In particular the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the THCV used is in the form of a botanically derived purified THCV. Alternatively, a synthetically produced THCV is used.

The present invention relates to crystalline forms of 6-hydroxy cannabidivarin (6-OH CBDV), methods for their production, and their use in therapy. The crystalline forms are easier to handle than other solid forms, such as glass amorphous material, and will useful in the manufacture of medicaments for the treatment of conditions associated with seizure.

A method of plant extraction comprising: (a) providing a plurality of trichomes from a plant at a first temperature below about 35 °C; and either: (b1) applying a negative pressure to the trichomes to volatize at least one desired compound from the trichomes to form a gaseous plant extract; and (c1) condensing the gaseous plant extract at a second temperature below about 25 °C to form a liquid plant extract; or (b2) combining the trichomes with a fluid to form a mixture; (c2) inducing cavitation in the mixture to release at least one desired compound from the trichome into the fluid; and (d2) separating out the at least one desired compound from the mixture; wherein the at least one desired compound is a terpene, a terpenoid, a cannabinoid, or a flavonoid.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidiol (6-0 H CBD), is a metabolite of CBD. The cannabinoid can be produced by synthetic means and a method for the production of 6-0 H CBD is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-0 H CBD in a model of disease.

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigero (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

A fatty acid ester of cannabinoid, wherein the fatty acid is an unsaturated acid, with an ester linkage consisting of an aryloxy oxygen directly bonded to an aromatic ring of the cannabinoid and a carbonyl group attached to the fatty acid unsaturated carbon chain.

A method is provided for the synthesis of (-)-trans-Δ9-tetrahydrocannabivarin (Δ9-THCV) and analogs thereof such that in the reaction product, the molar ratio of the Δ9 isomer to incidentally formed Δ8 isomers is greater than 4:1. Synthesis is carried out by combining a selected cannabinoid reactant, e.g., cannabidivarin (CBDV) or an analog thereof, with an acid in a solvent for the cannabinoid reactant, wherein the acid comprises (i) a Lewis acid having an acid softness index value in the range of -10 ΔG0 f, M n+ to ‑150 ΔG0 f, M n+, (ii) a Brønsted acid having a pKa in the range of -4.0 to +4.0, or (iii) a combination of (i) and (ii), under reaction conditions comprising a reaction temperature in the range of ‑0 °C to 25 °C and a reaction time in the range of 1 hour to 24 hours. The reaction is thereafter quenched with base and the solvent removed, wherein the crude reaction product so provided may be purified, e.g., chromatographically purified. Also provided is a method for synthesizing Δ9-THCV that further includes synthesis of the cannabinoid reactant. The invention additionally provides novel cannabinoid compositions that may be synthesized using the aforementioned methodology.

A transdermal delivery composition for the delivery to skin and the penetration of the skin includes: (a) a therapeutic effective amount of a cannabinoid mixture, wherein the cannabinoid mixture comprises cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) at a weight ratio of about 1:20 to about 20:1; (b) a hydrophilic polymer / hydrophobic polymer adduct in an amount sufficient to hold the cannabinoid composition and provide a sustain release of the cannabinoid mixture after application to skin tissue over a time period of at least 6 hours; (c) a penetrant component in an amount sufficient to assist with a transdermal penetration of the cannabinoid mixture through skin tissue once the composition has been applied to skin tissue; (d) a surfactant component in an amount sufficient to stabilize the polymer adduct and release the cannabinoid mixture from the transdermal delivery composition upon application to skin tissue; and (e) at least about 70 wt. % water. A method of application of a transdermal delivery composition to skin tissue includes applying the transdermal delivery composition to skin tissue and spreading the composition to form a film on the skin tissue. A method for formulating a transdermal delivery composition based on a desired penetration weight ratio of CBD to THC through skin tissue includes selecting a formulation weight ratio of CBD to THC for formulating the composition, wherein the weight ratio is determined by multiplying the desired penetration weight ratio of CBD to THC by a CBD / THC delivery factor, wherein the CBD / THC delivery factor.

The invention relates to a preparation method and application of cannabidiol epoxide, and the method comprises the following steps: obtaining cannabidiol, adding the cannabidiol into a buffer solution containing a surfactant, and treating under a preset treatment condition to obtain a crude product; and separating and purifying the crude product through silica gel column gradient chromatography to obtain a cannabidiol epoxide finished product. Compared with a traditional oxidation method adopting a peroxide agent, the process for preparing the cannabidiol epoxide can be obtained in one step through air natural oxidation, the cannabidiol epoxide is greener, more environmentally friendly and safer, and the production cost is lower while it is guaranteed that operation is easy. Meanwhile, the cannabidiol CBD which is relatively mature in extraction process is adopted as a raw material, and compared with other cannabinoids which are extremely low in natural content, the cannabidiol CBD is easier to obtain.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with Lennox-Gastaut syndrome (LGS) who are deemed to be treatment failures on their existing medication. In particular the use of CBD was found to provide a statistically significant reduction in both drop seizures and total seizure frequency in patients who have tried and failed anti-epileptic drugs (AEDs) or those who were currently taking AEDs but have uncontrolled seizures. Preferably the AEDs which have been shown to be treatment failures are one or more of rufinamide, lamotrigine, topiramate and / or felbamate. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The invention relates to a non-natural cannabinoid synthase comprising at least one amino acid variation as compared to a wild type cannabinoid synthase Δ9-tetrahydrocannabinolic acid synthase (THCAS), comprising three alpha helices (αA, αB and αC) where a disulfide bond is not formed between alpha helix αA and alpha helix αC, wherein the non-natural cannabinoid synthase catalyzes the oxidative cyclization of cannabigerolic acid (CBGA) into a cannabinoid. The invention further relates to a non-natural Δ9-tetrahydrocannabinolic acid synthase (THCAS), a non-natural cannabidiolic acid synthase (CBDAS), and a non-natural cannabichromenic acid synthase (CBCAS) comprising at least one amino acid variation as compared to a wild type THCAS, CBDAS, or CBCAS, respectively, comprising three alpha helices (αA, αB and αC) and wherein a disulfide bond is not formed between alpha helix αA and alpha helix αC. The invention also relates to a nucleic acid, expression construct, and engineered cell for making the non-natural THCAS, CBDAS, and / or CBCAS. Also provided are compositions comprising the non-natural THCAS, CBDAS, and / or CBCAS; isolated non-natural THCAS, CBDAS, and / or CBCAS enzymes; methods of making the isolated enzymes; cell extracts comprising cannabinoids; and methods of making cannabinoids.

Apparatus and methods are provided for dispensing into a liquid a soluble substance, such as a soluble flavoring. The soluble flavoring may include a lime flavoring with citric acid. It may include a cannabinoid. Alternatively, the soluble flavoring may not include citric acid or sugar. A useful application of the subject invention includes a lime flavoring held by a gelatinous elastic lime wedge. The gelatinous lime wedge may be retrieved from a protective covering and acted upon so it mixes the lime flavoring into a beverage, such as when it's inserted into a water or beer bottle or can. Rather than needing to buy and store a perishable natural lime, and cut it up, a gelatinous lime wedge holding soluble lime flavoring may be stored for an extended period of time, and placed in functional contact with water, beer, or other liquid, at time of consumption.

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of PTE.

A method for rapidly brewing a malt beverage having 0.00-0.49% alcohol by volume using yeast under aerobic or anaerobic conditions. The yeast undergoes fermentation (minimal yeast contact time) growth during either aerobic or anaerobic conditions, followed by inactivation by boiling. Beverage properties such as sweetness, aldehyde content, flavor actives, pH, mouthfeel, and heat are controlled to mimic popular beer styles. The beverage may be fortified with alcohol or rapidly fully fermented, thereby creating an alcoholic malt beverage containing greater than 0.49% alcohol by volume. The beverage may also be fortified with substances such as cannabis, terpenes, cannabinoids, cannabidiol (CBD), synthetic cannabinoids, mushrooms, or peyote to alter psychoactive or physiological properties. Kombucha, carbonated water, wine, or distilled spirits may also be produced in a rapid time frame using this method.

The present invention relates to a chewing gum for mucosal delivery of cannabinoids, the chewing gum including water-soluble chewing gum ingredients and water-insoluble gum base, wherein the gum base has one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the water-soluble chewing gum ingredients include one or more sugar alcohols in an amount of 35-80% by weight of the chewing gum, and wherein the chewing gum has one or more cannabinoids.

Described are liquid compositions that contain a desired (e.g., extracted) plant material such as cannabinoid, terpene, terpenoid, or the like, contained, e.g., dissolved, suspended, or emulsified, in the liquid, which contains surfactant; methods of preparing these types of liquid compositions; and methods of processing this type of liquid composition to collect, isolate, concentrate, or purify a desired target material contained in the liquid composition.

Described herein are novel oligosaccharides of cannabidiol and other cannabinoids and methods of production and uses thereof. The production method includes contacting cannabidiol with UDP-carbohydrate dependent glycosyltransferases (UGT73A class) to produce a cannabinoid-β-D-glycoside, then contacting the product with a cyclomaltodextrin glucanotransferase and a cyclodextrin to elongate the sugar moiety with (1-4)-α-D-glucopyranoside, thereby producing a mixed 0-a-structure in a recombinant host that has an amphiphilic structure as a surfactant solubilizer and different enzymatic degradability of α- and β-D-glucopyranose residues by amylases and β-glycosidases, thereby allowing targeted drug delivery.

Provided is a powder tea composition which enables a cannabinoid-containing food and beverages having a high tea leaf flavor and being capable of sufficiently enjoying the effect of cannabinoid to be produced. Provided is a powder tea composition in a powder form, including a cannabinoid-containing water-soluble granulated product and a tea leaf-ground product.

The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

Pharmaceutical compositions comprising one or more cannabinoids and a pharmaceutically acceptable carrier are disclosed. The compositions are in a form suitable for topical administration, and are useful in the treatment of pain. The cannabinoids suitable for use include cannabidiols, cannabinols, and various other naturally occurring and synthetic cannabinoids. The compositions may also further include anti-inflammatory agents, steroids, or terpenoids. In preferred embodiments, the cannabinoids incorporated in the compositions are cannabidiol (CBD) and cannabinol (CBN) while the carriers are selected from the group consisting of Labrasol™, Transcutol™, lecithin, lysolecithin, isopropyl palmitate, and isopropyl myristate.

The present disclosure may broadly provide composition for applying to food comprising a cannabidiol (CBD) having a purity greater than 90% and a tetrahydrocannabinol (THC) having a purity greater than 90% at a ratio of CBD:THC of about 5:1 to about 80:1, for a combined cannabinoid concentration of up to 15 g / L, a pharmaceutically compatible carrier oil, a pharmaceutically compatible emulsifier system, greater than 60% w / v water, and the composition having a viscosity of 500 to 5,000 cP at 21°C, a pH of between 4-7 and being in the form of an oil-in-water nanoemulsion.